-+ 0.00%
-+ 0.00%
-+ 0.00%

Candel Therapeutics To Present New Data From Phase 3 Clinical Trial Of Aglatimagene Besadenovec In Patients With Intermediate- To High-Risk Localized Prostate Cancer At AUA 2026 Annual Meeting Plenary Program

Benzinga·03/09/2026 12:17:57
Listen to the news

Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that an abstract was accepted for oral presentation in the Practice-changing, Paradigm-shifting Clinical Trials in Urology session, as part of the American Urological Association (AUA) 2026 Annual Meeting Plenary Program being held in Washington D.C. from May 15-18, 2026. The presentation will feature new data from the Company's phase 3 clinical trial of aglatimagene besadenovec (aglatimagene or CAN-2409) in patients with intermediate- to high-risk localized prostate cancer.